首个国产GLP-1减重创新药获批在即，非官方售价已曝光

Core Viewpoint - The first domestically developed GLP-1 weight loss drug, Masitide Injection, by Innovent Biologics is expected to be approved soon, potentially disrupting the current market dominated by multinational giants Novo Nordisk and Eli Lilly [1][2]. Company Summary - Innovent Biologics (1801.HK) experienced a stock price decline of approximately 5% as of June 26, 2025, despite the anticipated approval of Masitide for both weight loss and diabetes indications within the year [1]. - Masitide is the world's first dual receptor agonist for GCG/GLP-1, which could enhance the accessibility of GLP-1 weight loss medications [1]. Product Pricing and Availability - Initial pricing for Masitide is projected to be around 1,000 to 1,600 RMB for a 2mg two-pack, with higher prices for larger quantities [2]. - The drug is expected to be available in both public and private hospitals simultaneously, with private hospitals already accepting reservations for the product [1][2]. Market Outlook - The global weight loss drug market is projected to reach $150 billion by 2030, while the domestic GLP-1 weight loss drug market in China is estimated to approach 40 billion RMB by the same year [3]. - Increased competition from more weight loss drugs entering the market is likely to lead to a decrease in overall prices for GLP-1 medications [3].